GSK and Hengrui Pharma forge strategic partnership to co-develop up to 12 innovative medicines
GSK has taken another major step in strengthening its innovation pipeline by entering a broad partnership with China's Jiangsu Hengrui MedicineDealroom has a profile for this one. Try Dealroom →. The deal covers the potential co-development of up to 12 drug programs across oncology, respiratory, immunology, and inflammation — including a promising dual PDE3/4 inhibitor for COPD that could emerge as a best-in-class therapy.
As part of the agreement, GSK will make an upfront payment of $500 million, with additional milestone payments that could exceed $12 billion, tied to development, regulatory approvals, and commercial performance. Hengrui will lead early-stage development through Phase 1, including patient studies outside China. After that point, GSK will hold exclusive options to license each program individually.
One standout asset is HRS-9821, a molecule designed to help COPD patients who remain symptomatic despite current treatments. With a dual-action mechanism and dry powder inhalation format, the compound aligns closely with GSK’s experience in respiratory therapeutics.
For GSK, the alliance offers a chance to deepen its respiratory pipeline and expand into mid- to long-term assets with global potential. For Hengrui, it marks a significant leap in its international expansion strategy, positioning the company as a key source of pharmaceutical innovation on the global stage.
Source:
A.M.
